Elanco Animal Health (ELAN) said Monday it has sold certain future tiered royalties and commercial milestones of its lotilaner ophthalmic solution Xdemvy 0.25% to funds affiliated with Blackstone's (BX) Blackstone Life Sciences and Blackstone Credit & Insurance for $295 million in cash.
The company said it will use the proceeds to pay down debt.
Elanco said the deal applies to certain tiered royalties linked to the US net sales of Xdemvy from April 2025 to August 2033 as well as certain commercial milestones.
The company said it continues to hold the rights to all royalty payments on net sales outside US and on any future applications of lotilaner beyond ophthalmic solutions.
Elanco's stock rose 2% in recent Monday premarket activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.